Drug shortages
HHS proposes policies to prevent drug shortages. Find out how AHA is collaborating with the private sector to mitigate supply chain vulnerabilities.
The Food and Drug Administration today recommended strategies for health care providers to conserve prefilled 0.9% sodium chloride intravenous lock/flush syringes.
Pending federal approval, Civica Rx, the nonprofit consortium of U.S. hospitals, plans to manufacture and distribute several generic insulins, continuing its mission to alleviate chronic shortages of inpatient drugs and reduce drug prices.
A new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine recommends actions to help prevent medical product shortages and ensure access to essential drugs and devices.
Intermountain Healthcare has agreed to sell its Intalere group purchasing organization (formerly Amerinet) to Vizient, a GPO that also provides data analytics and performance-improvement insights to health systems.
Leading healthcare groups convened a summit, “Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security,” on July 27-31 to examine the resilience of the U.S. pharmaceutical supply chain in light of the current state of global pharmaceutical manufacturing.
Reps. Scott Peters, D-Calif., Eliot Engel, D-N.Y., Brett Guthrie, R-KY, Anna Eshoo, D-Calif., Richard Hudson, R-N.C., Michael McCaul, R-Texas, Kurt Schrader, D-Ore., and Gus Bilirakis, D-Fla., introduced the Preventing Drug Shortages Act (H.R. 6080).
AHA, health organizations letter to Senate Chairman, Lamar Alexander and Ranking Member Patty Murray, expressing support of S.2723 - The Mitigating Emergency Drug Shortages (MEDS) Act.
AHA, health organizations letter to Representatives Peters, Engel, Eshoo, Schrader, Guthrie, Hudson, McCaul, and Bilirakis, supporting the Preventing Drug Shortages Act.
AHA, others urge Senate HELP Committee to advance MEDS Act (S.2723).
The Food and Drug Administration today released a proposed rule that would allow states and other non-federal government entities to establish programs to import certain FDA-approved prescription drug and biological products from Canada.